BBIO: Oppenheimer Initiates
Oppenheimer assumes BridgeBio Oncology at Outperform with a price target of $22
Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22
Oppenheimer assumes BridgeBio Oncology at Outperform with a price target of $22
Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22